Guggenheim Initiates Coverage On Roivant Sciences with Buy Rating, Announces Price Target of $17
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Yatin Suneja initiates coverage on Roivant Sciences (NASDAQ:ROIV) with a Buy rating and announces a price target of $17.
October 17, 2023 | 3:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Roivant Sciences receives a Buy rating from Guggenheim with a price target of $17.
The Buy rating from Guggenheim indicates a positive outlook for Roivant Sciences. The price target of $17 suggests that the analyst believes the stock has significant upside potential. This could lead to increased investor interest and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100